References
- Saro C, Sicilia B. Inflammatory bowel diseases: a disease (s) of modern times? Is incidence still increasing? World J. Gastroenterol.14(36), 5491–5498 (2008).
- Koloski NA, Bret L, Radford-Smith G. Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature. World J. Gastroenterol.14(2), 165–173 (2008).
- Sood A, Midha V. Epidemiology of inflammatory bowel disease in Asia. Indian J. Gastroenterol.26(6), 285–289 (2007).
- Hayee B, Rahman FZ, Sewell G, Smith AM, Segal AW. Crohn’s disease as an immunodeficiency. Expert Rev. Clin. Immunol.6(4), 585–596 (2010).
- Behr M, Lalande J-D. Mycobacteria in Crohn’s disease: how innate immune deficiency may result in chronic inflammation. Expert Rev. Clin. Immunol.6(4), 633–641 (2010).
- Van Wijk F, Cheroutre H. Mucosal T cells in gut homeostasis and inflammation. Expert Rev. Clin. Immunol.6(4), 559–566 (2010).
- Pallone F, Fina D, Caruso R, Monteleone G. The role of IL-21 in inflammatory bowel disease. Expert Rev. Clin. Immunol.6(4), 537–541 (2010).
- Otley AR, Russell RK, Day AS. Nutritional therapy for the treatment of pediatric Crohn’s disease. Expert Rev. Clin. Immunol.6(4), 667–676 (2010).
- Ferguson LR. Nutrigenomics and inflammatory bowel diseases. Expert Rev. Clin. Immunol.6(4), 573–583 (2010).
- Bousvaros A. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. Expert Rev. Clin. Immunol.6(4), 659–666 (2010).
- Shah B, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev. Clin. Immunol.6(4), 607–620 (2010).
- Dahan A, Amidon GL, Zimmermann EM. Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update. Expert Rev. Clin. Immunol.6(4), 543–550 (2010).
- Bernick SJ, Kane S. Insight into the widespread problem of nonadherence to therapy in ulcerative colitis patients. Expert Rev. Clin. Immunol.6(4), 677–682 (2010).
- Caccaro R, D’Incà R, Sturniolo GC. Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease. Expert Rev. Clin. Immunol.6(4), 551–558 (2010).
- Lawlor G, Ahmed A, Moss AC. Once-daily mesalamine granules for ulcerative colitis. Expert Rev. Clin. Immunol.6(4), 521–526 (2010).
- Bickston SJ, Muniyappa K. Natalizumab for the treatment of Crohn’s disease. Expert Rev. Clin. Immunol.6(4), 513–519 (2010).
- Fiorino G, Correale C, Fries W, Repici A, Malesci A, Danese S. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. Expert Rev. Clin. Immunol.6(4), 607–620 (2010).
- Panés J, Ordás I, Ricart E. Stem cell treatment for Crohn’s disease. Expert Rev. Clin. Immunol.6(4), 597–605 (2010).
- Bewtra M, Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev. Clin. Immunol.6(4), 621–631 (2010).
- Kwan LY, Mahadevan U. Inflammatory bowel disease and pregnancy: an update. Expert Rev. Clin. Immunol.6(4), 643–657 (2010).